Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29782972 | 0.75 | CES2 (0.46) | CES2CES1PARP1 | |
| SCHEMBL7146004 | 0.75 | CES2 (0.46) | CES2CES1PARP1 | |
| SCHEMBL12481336 | 0.73 | LMNA (0.36) | PBRM1 | |
| SCHEMBL16649590 | 0.71 | NOTUM (0.33) | PBRM1 | |
| SCHEMBL29467978 | 0.71 | CES2 (0.40) | CES2CES1PARP1PBRM1 | |
| SCHEMBL201485 | 0.70 | HSD17B1 (0.44) | CES2CES1 | |
| SCHEMBL6818860 | 0.70 | PBRM1 (0.41) | CES2CES1PARP1PBRM1 | |
| SCHEMBL17275022 | 0.70 | CES2 (0.38) | CES2CES1PARP1 | |
| SCHEMBL30739599 | 0.70 | CES2 (0.38) | CES2CES1PARP1 | |
| SCHEMBL378789 | 0.69 | KEAP1 (0.41) | CES2CES1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | ALLISON BRETT D | 2008-03-27 | — | — | US | disclosed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7288651-B2 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| EP-1651622-B1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | EP | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | ERN1 4282/4885CES2 1264/4885CES1 2028/4885 |
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | ERN1 4282/4885CES2 1264/4885CES1 2028/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | ERN1 3053/4885CES2 1335/4885CES1 946/4885 |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | ERN1 3053/4885CES2 1335/4885CES1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.